These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16158412)

  • 1. Using propensity scores to estimate the cost-effectiveness of medical therapies.
    Indurkhya A; Mitra N; Schrag D
    Stat Med; 2006 May; 25(9):1561-76. PubMed ID: 16158412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data.
    Mitra N; Indurkhya A
    Health Econ; 2005 Aug; 14(8):805-15. PubMed ID: 15791679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
    Thompson KM; Tebbens RJ
    Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical model of cost of bladder cancer in the elderly.
    Cooksley CD; Avritscher EB; Grossman HB; Sabichi AL; Dinney CP; Pettaway C; Elting LS
    Urology; 2008 Mar; 71(3):519-25. PubMed ID: 18342201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
    Nixon RM; Wonderling D; Grieve RD
    Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
    Nelson CL; Sun JL; Tsiatis AA; Mark DB
    Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving efficiency and value in palliative care with net benefit regression: an introduction to a simple method for cost-effectiveness analysis with person-level data.
    Hoch JS
    J Pain Symptom Manage; 2009 Jul; 38(1):54-61. PubMed ID: 19615627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit adequacy among elderly Social Security retired-worker beneficiaries and the SSI federal benefit rate.
    Rupp K; Strand A; Davies P; Sears J
    Soc Secur Bull; 2007; 67(3):29-51. PubMed ID: 18605217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF.
    Woodward RM; Brown ML; Stewart ST; Cronin KA; Cutler DM
    Cancer; 2007 Dec; 110(11):2511-8. PubMed ID: 17955504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
    Spiegelhalter DJ; Best NG
    Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.
    Hoch JS; Rockx MA; Krahn AD
    BMC Health Serv Res; 2006 Jun; 6():68. PubMed ID: 16756680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.